Interleukin-13 (human, recombinant)

ALRH Protein|IL-13

Interleukin-13 (IL-13) is a cytokine that is involved in type 2 immunity.{21555,69683,69684} It is a secreted protein that is mainly expressed by activated T cells, but is also produced by mast cells, basophils, eosinophils, and nuocytes.{69685,69684} Two amino acid sequences of IL-13 have been reported; one is 132 amino acids in length and the other with 14 additional amino acids at the N-terminus resulting in a 146 amino acid protein.{69685,69686,69687} IL-13 binds to a heterodimer of IL-4 receptor α (IL-4Rα) and IL-13Rα1 to initiate intracellular signaling through the JAK/STAT or PI3K pathways.{69684,9249} It also binds to the decoy receptor, IL-13Rα2, to initiate TGF-β signaling.{21555,69686,69684} IL-13 has roles in host defense against helminth parasites, airway hyperresponsiveness, antitumor immunity, tissue remodeling, and mucus production.{21555,69684} It induces the proliferation of activated B lymphocytes and the production of IgG and IgM by B cells co-cultured with T cells.{69685} Knockout of Il13 increases survival and decreases hepatic fibrosis in a mouse model of S. mansoni infection.{21551} SNPs in IL13 are associated with asthma.{69684} Protein levels of IL-13 are increased in primary and metastatic tumors compared with normal ovarian tissue in patients with ovarian cancer.{69688} Cayman’s Interleukin-13 (human, recombinant) protein is based on the 132 amino acid sequence and can be used for cell-based assay applications.

-80

-80

Lyophilized from sterile PBS, pH 7.4

365

≥92% estimated by SDS-PAGE